UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

THERABIOGEN, INC.

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

88338E107

(CUSIP Number)

February 16, 2012

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[_] Rule 13d-1(b)

[ ] Rule 13d-1(c)

[X] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 88338E107

1) Names of Reporting Persons. LeadDog Capital, LP

I.R.S. Identification Nos. of Above Persons (entities only)

22-3967904

2) Check the Appropriate Box if a Member of a Group (a) [ ]

(See Instructions) (b) [ X ]

3) SEC Use Only

4) Citizenship or Place of Organization Delaware

NUMBER OF	5) Sole Voting Power 1,722,816 (a)
SHARES
BENEFICIALLY	6) Shared Voting Power -0-
OWNED BY
EACH
REPORTING	7) Sole Dispositive Power 1,722,816 (a)
PERSON
WITH:	8) Shared Dispositive Power -0-

9) Aggregate Amount Beneficially Owned by Each Reporting Person

1,722,816 (a)

10) Check if the Aggregate Amount in Row (9) Excludes

Certain Shares (See Instructions) [ ]

11) Percent of Class Represented by Amount in Item 9

2.99% (a)

12) Type of Reporting Person (See Instructions)

(a) LeadDog Capital, LP (“LeadDog LP”) is the beneficial owner of approximately 825,000 of convertible promissory notes (“Notes”) and convertible debentures (“Debentures”) that may be converted into common stock of TheraBiogen, Inc., formerly known as Kushi Resources, Inc. (“Issuer”). The Notes and underlying common stock are being held pursuant to the terms of several escrow agreements. The terms of the Notes and the Debentures prohibit LeadDog LP from converting the Notes and Debentures to the extent such conversion would result in LeadDog LP and its affiliates beneficially owning (as determined in accordance with Section 13(d) of the Securities and Exchange Act of 1934 (“Exchange Act”)and the rules promulgated thereunder) in excess of 9.5% of the then issued and outstanding shares of common stock, including the shares issuable upon a conversion. Although LeadDog LP has sole voting and dispositive control of the common stock upon purchase, Chris Messalas and Joseph B. LaRocco as managing members of LeadDog Capital Markets, LLC (LeadDog LP’s general partner) may be deemed to have the right to direct the voting and dispositive control over such common stock. LeadDog Capital Markets, LLC is considered an affiliate of LeadDog LP so the combined beneficial ownership of LeadDog LP and LeadDog Capital Markets, LLC cannot exceed 9.5% of the then issued and outstanding shares of common stock of the Issuer, including the shares issuable upon a conversion.

CUSIP No. 88338E107

1) Names of Reporting Persons. LeadDog Capital Markets, LLC

I.R.S. Identification Nos. of Above Persons (entities only)

80-0325704

2) Check the Appropriate Box if a Member of a Group (a) [ ]

(See Instructions) (b) [ X ]

3) SEC Use Only

4) Citizenship or Place of Organization New York

NUMBER OF	5) Sole Voting Power 367,195 (a)
SHARES
BENEFICIALLY	6) Shared Voting Power -0-
OWNED BY
EACH
REPORTING	7) Sole Dispositive Power 367,195 (a)
PERSON
WITH:	8) Shared Dispositive Power -0-

9) Aggregate Amount Beneficially Owned by Each Reporting Person

367,195 (a)

10) Check if the Aggregate Amount in Row (9) Excludes

Certain Shares (See Instructions) [ ]

11) Percent of Class Represented by Amount in Item 9

.64% (a) (b)

12) Type of Reporting Person (See Instructions)

(a) LeadDog Capital Markets, LLC (“LeadDog LLC”) is the beneficial owner of convertible promissory notes (“Notes”) and convertible debentures (“Debentures”) that may be converted into common stock of TheraBiogen, Inc., formerly known as Kushi Resources, Inc. (“Issuer”). The Notes and underlying common stock are being held pursuant to the terms of several escrow agreements. The terms of the Notes and the Debentures prohibit LeadDog LLC from converting the Notes and Debentures to the extent such conversion would result in LeadDog LLC and its affiliates beneficially owning (as determined in accordance with Section 13(d) of the Securities and Exchange Act of 1934 (“Exchange Act”)and the rules promulgated thereunder) in excess of 9.5% of the then issued and outstanding shares of common stock, including the shares issuable upon a conversion. Although LeadDog LLC has sole voting and dispositive control of the common stock upon purchase, Chris Messalas and Joseph B. LaRocco as managing members of LeadDog Capital Markets, LLC (the general partner of LeadDog LP) may be deemed to have the right to direct the voting and dispositive control over such common stock. LeadDog Capital Markets, LLC is considered an affiliate of LeadDog LP so the combined beneficial ownership of LeadDog LP and LeadDog Capital Markets, LLC cannot exceed 9.5% of the then issued and outstanding shares of common stock of the Issuer, including the shares issuable upon a conversion.

ITEM 1.

(A)	NAME OF ISSUER

	TheraBiogen, Inc., formerly known as Kushi Resources, Inc.

(B)	ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICE

	4400 Route 9 South, Suite 1000 Freehold, NJ 07728

ITEM 2.

(A)	NAME OF PERSONS FILING

	LeadDog Capital, LP (Delaware) and LeadDog Capital Markets, LLC (New York) Chris Messalas and Joseph B. LaRocco as managing members of LeadDog Capital Markets, LLC (LeadDog Capital, LP’s general partner) have the right to direct the voting and dispositive control over such common stock owned by LeadDog Capital, LP and LeadDog Capital Markets, LLC.

(B)	ADDRESS OF PRINCIPAL BUSINESS OFFICE OR IF NONE, RESIDENCE

	55 Broad Street, 24th Floor New York, NY 10004

(C)	CITIZENSHIP

	LeadDog Capital, LP (Delaware) and LeadDog Capital Markets, LLC (New York)

(D)	TITLE OF CLASS OF SECURITIES

	Common Stock

(E)	CUSIP NUMBER

	88338E107

ITEM 3.

If this statement is filed pursuant to rule 240.13d- 1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not Applicable.

ITEM 4. OWNERSHIP.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

		LeadDog LP	LeadDog LLC
a.	Beneficial Ownership	1,722,816	367,195
b.	Percentage of Class	2.99%	.64%
c.	Sole Voting Power	1,722,816	367,195
	Shared Voting Power	-0-	-0-
	Sole Dispositive Power	1,722,816	367,195
	Shared Dispositive Power	-0-	-0-

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following /___/.

See Item 4 above.

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not Applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not Applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

See Item 2 section A above.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP

Not Applicable.

ITEM 10. CERTIFICATION.

By signing below I certify that, to the best of my knowledge and belief, thesecurities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

	LeadDog Capital, LP by its General Partner LeadDog Capital Markets, LLC

Dated: February 16, 2012	By:	/s/ Chris Messalas
		Name: Chris Messalas
		Title: Managing Member

	LeadDog Capital Markets, LLC

	By:	/s/ Chris Messalas
		Name: Chris Messalas
		Title: Managing Member

JOINT FILING AGREEMENT

JOINT FILING AGREEMENT made as of this 16th day of February, 2012 by and among LeadDog Capital, LP ("LeadDog LP") and LeadDog Capital Markets, LLC (“LeadDog LLC”).

WHEREAS, LeadDog LP and LeadDog LLC collectively through the ownership of convertible notes and convertible debentures are entitled to beneficially own more than five (5%) percent but not more than nine and one-half percent (9.5%) of the issued and outstanding common stock, $.001 par value of TheraBiogen, Inc. formerly known as Kushi Resources, Inc. ("TheraBiogen Common Stock"), a Nevada corporation; and

WHEREAS, pursuant to Section 13(g) of the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder, the parties hereto are required to file a Schedule 13G with the Securities and Exchange Commission ("SEC").

NOW, THEREFORE, the parties agree as follows:

1. LeadDog LP and LeadDog LLC hereby agree to jointly file this Schedule 13G with the SEC regarding the beneficial ownership of TheraBiogen Common Stock and to file any and all amendments and supplements thereto.

2. This Agreement contains the entire agreement among the parties concerning the subject matter hereof and may not be amended, modified or changed except pursuant to a written instrument signed by all parties.

IN WITNESS WHEREOF, the parties have signed this Agreement the day and year first above written.

	LeadDog Capital, LP by its General Partner LeadDog Capital Markets, LLC

Dated: February 16, 2012	By:	/s/ Chris Messalas
		Name: Chris Messalas
		Title: Managing Member

	LeadDog Capital Markets, LLC

	By:	/s/ Chris Messalas
		Name: Chris Messalas
		Title: Managing Member

TheraBiogen, Inc. SC 13G/A